SCHEMBL19734745

SCHEMBL19734745

C[C@H](NC(=O)OC(C)(C)C)C(=O)NC1CCN(C(=O)OCc2ccccc2)CC1

nearest known ligand 0.56

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 2/20 0.56
MEN1 O00255 2/20 0.51
KMT2A Q03164 2/20 0.51
MAPT P10636 2/20 0.51
MAPK1 P28482 2/20 0.51
NPSR1 Q6W5P4 2/20 0.51
ALDH1A1 P00352 1/20 0.51
POLB P06746 1/20 0.51
NTSR1 P30989 1/20 0.51
SMN1; SMN2 Q16637 3/20 0.50
NPC1 O15118 2/20 0.50
RAB9A P51151 2/20 0.50
HTT P42858 1/20 0.49
CYP2C19 P33261 1/20 0.48
HRH2 P25021 2/20 0.48
HRH1 P35367 2/20 0.48
CTSL P07711 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL951538 0.88 KMT2A (0.59) L3MBTL1MEN1KMT2AMAPTMAPK1
SCHEMBL16011173 0.85 KLK5 (0.57) L3MBTL1MEN1KMT2AMAPTMAPK1
SCHEMBL19716705 0.85 KLK5 (0.57) L3MBTL1MEN1KMT2AMAPTMAPK1
SCHEMBL16466559 0.84 CTSL (0.53) MEN1KMT2AMAPK1NPSR1ALDH1A1
SCHEMBL16465560 0.84 CTSL (0.53) MEN1KMT2AMAPK1NPSR1ALDH1A1
SCHEMBL27145154 0.84 CTSL (0.53) MEN1KMT2AMAPK1NPSR1ALDH1A1
Iodide SCHEMBL789903 0.84 L3MBTL1 (0.48) L3MBTL1MEN1KMT2AMAPTMAPK1
Iodide SCHEMBL789904 0.84 L3MBTL1 (0.48) L3MBTL1MEN1KMT2AMAPTMAPK1
SCHEMBL17946176 0.84 GPR119 (0.54) L3MBTL1MEN1KMT2AMAPK1SMN1; SMN2
SCHEMBL20329576 0.84 GPR119 (0.54) L3MBTL1MEN1KMT2AMAPK1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3468953-B1 SUBSTITUTED PYRIDINES AS INHIBITORS OF DNMT1 GLAXOSMITHKLINE IP DEV LTD (GB) 2024-05-22 EP disclosed
US-10975056-B2 Substituted pyridines as inhibitors of DNMT1 GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2021-04-13 US disclosed
US-20190194166-A1 SUBSTITUTED PYRIDINES AS INHIBITORS OF DNMT1 GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2019-06-27 US disclosed
WO-2017216727-A1 SUBSTITUTED PYRIDINES AS INHIBITORS OF DNMT1 GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2017-12-21 WO disclosed
WO-2017216726-A1 SUBSTITUTED PYRIDINES AS INHIBITORS OF DNMT1 GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2017-12-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10975056-B2 Substituted pyridines as inhibitors of DNMT1 DNMT1, DNMT3A, DNMT3B L3MBTL1 1537/4885MEN1 1594/4885KMT2A 121/4885
US-20190194166-A1 SUBSTITUTED PYRIDINES AS INHIBITORS OF DNMT1 DNMT1, DNMT3A, DNMT3B L3MBTL1 1537/4885MEN1 1594/4885KMT2A 121/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.